[go: up one dir, main page]

SE9401091D0 - Alphavirus cDNA vectors - Google Patents

Alphavirus cDNA vectors

Info

Publication number
SE9401091D0
SE9401091D0 SE9401091A SE9401091A SE9401091D0 SE 9401091 D0 SE9401091 D0 SE 9401091D0 SE 9401091 A SE9401091 A SE 9401091A SE 9401091 A SE9401091 A SE 9401091A SE 9401091 D0 SE9401091 D0 SE 9401091D0
Authority
SE
Sweden
Prior art keywords
present
cdna
polynucleotide molecules
animal
desired products
Prior art date
Application number
SE9401091A
Other languages
English (en)
Swedish (sv)
Inventor
Peter Liljestroem
Henrik Garoff
Original Assignee
Bioption Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20393495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9401091(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioption Ab filed Critical Bioption Ab
Priority to SE9401091A priority Critical patent/SE9401091D0/xx
Publication of SE9401091D0 publication Critical patent/SE9401091D0/xx
Priority to JP7525612A priority patent/JPH09511143A/ja
Priority to AU21557/95A priority patent/AU699384B2/en
Priority to ES95914666T priority patent/ES2223051T3/es
Priority to CA002184261A priority patent/CA2184261A1/en
Priority to DE69533130T priority patent/DE69533130T2/de
Priority to DK95914666T priority patent/DK0753053T3/da
Priority to AT95914666T priority patent/ATE268813T1/de
Priority to PCT/SE1995/000343 priority patent/WO1995027044A1/en
Priority to EP95914666A priority patent/EP0753053B1/en
Priority to FI963860A priority patent/FI963860A/fi
Priority to US09/061,912 priority patent/US6566093B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/123—Hepatitis delta
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/52—Vector systems having a special element relevant for transcription encoding ribozyme for self-inactivation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SE9401091A 1994-03-31 1994-03-31 Alphavirus cDNA vectors SE9401091D0 (sv)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE9401091A SE9401091D0 (sv) 1994-03-31 1994-03-31 Alphavirus cDNA vectors
EP95914666A EP0753053B1 (en) 1994-03-31 1995-03-30 ALPHAVIRUS cDNA VECTORS
PCT/SE1995/000343 WO1995027044A1 (en) 1994-03-31 1995-03-30 ALPHAVIRUS cDNA VECTORS
ES95914666T ES2223051T3 (es) 1994-03-31 1995-03-30 Vectores de adnc de alfavirus.
AU21557/95A AU699384B2 (en) 1994-03-31 1995-03-30 Alphavirus cDNA vectors
JP7525612A JPH09511143A (ja) 1994-03-31 1995-03-30 アルファーウイルスｃＤＮＡベクター
CA002184261A CA2184261A1 (en) 1994-03-31 1995-03-30 Alphavirus cdna vectors
DE69533130T DE69533130T2 (de) 1994-03-31 1995-03-30 VEKTOREN DER ALPHAVIRUS cDNA
DK95914666T DK0753053T3 (da) 1994-03-31 1995-03-30 Alfavirus-cDNA-vektorer
AT95914666T ATE268813T1 (de) 1994-03-31 1995-03-30 Vektoren der alphavirus cdna
FI963860A FI963860A (fi) 1994-03-31 1996-09-27 Alfavirus-cDNA-vektorit
US09/061,912 US6566093B1 (en) 1994-03-31 1998-04-17 Alphavirus cDNA vectors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9401091A SE9401091D0 (sv) 1994-03-31 1994-03-31 Alphavirus cDNA vectors

Publications (1)

Publication Number Publication Date
SE9401091D0 true SE9401091D0 (sv) 1994-03-31

Family

ID=20393495

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9401091A SE9401091D0 (sv) 1994-03-31 1994-03-31 Alphavirus cDNA vectors

Country Status (12)

Country Link
US (1) US6566093B1 (xx)
EP (1) EP0753053B1 (xx)
JP (1) JPH09511143A (xx)
AT (1) ATE268813T1 (xx)
AU (1) AU699384B2 (xx)
CA (1) CA2184261A1 (xx)
DE (1) DE69533130T2 (xx)
DK (1) DK0753053T3 (xx)
ES (1) ES2223051T3 (xx)
FI (1) FI963860A (xx)
SE (1) SE9401091D0 (xx)
WO (1) WO1995027044A1 (xx)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6465634B1 (en) 1996-04-05 2002-10-15 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5811407A (en) 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6432699B1 (en) 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
KR100556864B1 (ko) 1997-05-13 2006-03-10 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 렌티바이러스-기원 유전자 전달 벡터
FI110323B (fi) 1997-06-02 2002-12-31 Timo Korpela Rekombinanttikonstrukti geenin ilmentämisen lisäämiseksi kasveissa
WO1999025859A1 (en) * 1997-11-14 1999-05-27 Connaught Laboratories Limited Alphavirus vectors
EP1707633A1 (en) * 1997-11-14 2006-10-04 Sanofi Pasteur Limited Alphavirus vectors for paramyxovirus vaccines
US6475780B1 (en) 1997-11-14 2002-11-05 Aventis Pasteur Limited Alphavirus vectors for paramyxovirus vaccines
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
WO2001030847A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
PT1232264E (pt) 1999-11-18 2009-11-26 Novartis Vaccines & Diagnostic Gene fgf-21 humano e produtos da expressão do gene
JP2003531583A (ja) 2000-03-08 2003-10-28 カイロン コーポレイション ヒトｆｇｆ−２３遺伝子および遺伝子発現産物
PT1282702E (pt) 2000-05-10 2007-02-28 Ludwig Inst Cancer Res Polipéptidos imunogénicos codificados por minigenes mage e suas utilizações
DK1285080T3 (da) 2000-05-31 2008-12-01 Novartis Vaccines & Diagnostic Fremgangsmåde til oprensning af alphavirusreplikonpartikler
WO2002020721A2 (en) 2000-09-07 2002-03-14 University Of North Carolina At Chapel Hill Vectors derived from south african arbovirus no. 86
CN1520303B (zh) * 2001-03-27 2013-04-24 纽约大学 利用基于α病毒且靶向高亲和性层粘连蛋白受体的载体进行肿瘤治疗
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
ATE437222T1 (de) 2001-09-06 2009-08-15 Alphavax Inc Alphavirus replikon-vektorsysteme
IL163988A0 (en) 2002-03-15 2005-12-18 Wyeth Corp Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
AU2003223527B2 (en) 2002-04-09 2009-01-15 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US20050221493A1 (en) * 2002-12-04 2005-10-06 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
JP4991108B2 (ja) 2002-12-13 2012-08-01 アルファバックス，インコーポレイティド 多抗原性アルファウイルス・レプリコン粒子及び方法
BR122019005271B1 (pt) 2002-12-13 2020-10-13 Alphavax, Inc. método para a preparação de partículas de replicon de alfavírus (arps)
DK1608762T3 (da) 2003-03-20 2014-04-07 Alphavax Inc Forbedrede alphavirusreplikoner og hjælperkonstrukter
EP1651666B1 (en) 2003-07-11 2009-05-27 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
US7910093B2 (en) 2003-08-19 2011-03-22 New York University Method for detecting cancer cells and monitoring cancer therapy
DE602004032365D1 (de) * 2003-10-08 2011-06-01 Sanofi Pasteur Inc Modifizierter cea/b7-vektor
CN1980955A (zh) * 2004-04-29 2007-06-13 北卡罗来纳-查佩尔山大学 增强细胞粘连特性的方法和组合物
ATE420965T1 (de) 2004-05-18 2009-01-15 Alphavax Inc Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
FI20040704A0 (fi) * 2004-05-21 2004-05-21 Ari Hinkkanen Replikatiivisen viruksen tai sen rekombinantin käyttö terapiassa
CA2572921C (en) 2004-07-09 2017-01-03 The University Of North Carolina At Chapel Hill Replication-competent and propagation-defective venezuelan equine encephalitis (vee) viral adjuvants
AU2006302794B2 (en) 2005-02-15 2011-08-04 Children's Hospital, Inc. New live virus vaccines
US7303898B2 (en) * 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
FR2887259B1 (fr) * 2005-06-21 2007-09-14 Agronomique Inst Nat Rech CONSTRUCTION D'ADNc D'ALPHAVIRUS DE SALMONIDES
CA2689588C (en) 2007-06-21 2016-08-23 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
JP5663474B2 (ja) * 2008-05-23 2015-02-04 フィット バイオテク オーワイ アルファウイルスレプリカーゼをコードする発現ベクターおよび免疫アジュバントとしてのその使用
CL2008002322A1 (es) * 2008-08-07 2009-06-05 Univ Concepcion Formulacion farmaceutica veterinaria que comprende un sistema vectorial viral constituido por una particula recombinante de arn que codifica una cu/zn superoxido dismutasa de la bacteria patogena de bovinos brucella abortus, y al menos un alfavirus arn perteneciente a la familia del virus semliki forest (sfv), util como vacuna.
WO2011038063A1 (en) 2009-09-28 2011-03-31 The Trustees Of The University Of Pennsylvania Method of diagnosing and treating interstitial cystitis
US9198975B2 (en) 2010-12-01 2015-12-01 The University Of North Carolina At Chapel Hill Methods and compositions for targeting sites of neovascular growth
MX2022001468A (es) 2019-08-09 2022-07-19 Nutcracker Therapeutics Inc Metodos y aparatos de fabricación para remover material de una composición terapeutica.
CN115197964A (zh) * 2021-04-12 2022-10-18 华南农业大学 一种改进型pSFV1载体及其制备方法与应用
CN113549652A (zh) * 2021-07-21 2021-10-26 华农（肇庆）生物产业技术研究院有限公司 SFV-helper质粒、pSFVCs-LacZ病毒样颗粒及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
SE9003978D0 (sv) * 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DK0814154T3 (da) 1993-09-15 2009-08-31 Novartis Vaccines & Diagnostic Rekombinante alfavirusvektorer

Also Published As

Publication number Publication date
FI963860A0 (fi) 1996-09-27
ES2223051T3 (es) 2005-02-16
JPH09511143A (ja) 1997-11-11
AU699384B2 (en) 1998-12-03
ATE268813T1 (de) 2004-06-15
DE69533130T2 (de) 2005-07-07
WO1995027044A1 (en) 1995-10-12
EP0753053B1 (en) 2004-06-09
US6566093B1 (en) 2003-05-20
CA2184261A1 (en) 1995-10-12
FI963860A (fi) 1996-09-27
EP0753053A1 (en) 1997-01-15
DK0753053T3 (da) 2004-10-11
AU2155795A (en) 1995-10-23
DE69533130D1 (de) 2004-07-15

Similar Documents

Publication Publication Date Title
DK0753053T3 (da) Alfavirus-cDNA-vektorer
ATE227587T1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
DE60143292D1 (de) Varianten des menschlichen Koagulationsfaktors VII
ATE352633T1 (de) Expressionsvektor des alphavirus
IT7927940A0 (it) Estrattore chirurgico per asportare corpi estranei che si trovano nelle vie naturali del corpo umano, come calcoli e simili.
EP0365598A4 (en) Therapeutic antimicrobial polypeptides, their use and methods for preparation
ES557100A0 (es) Un metodo de produccion de un polipeptido con actividad de proteina c humana en una celula huesped
DE69230993D1 (de) Rekombinante viren vektoren zur expression in muskelzellen
FI844510A0 (fi) Ensym-resistenta immunsystemet modulerande peptider.
ATE230985T1 (de) Verwendung von xanthophyllen zur herstellung von arzneimitteln zur verbesserung der muskel- funktionsdauer oder zur behandlung von muskelstörungen oder erkrankungen
ATE95060T1 (de) Verwendung von c-22 bis c-26-aliphatischen alkoholen zur behandlung entzuendlicher und viraler hauterkrankungen.
ATE454403T1 (de) Menschliche koagulationsfaktor vii polypeptide
MXPA03001984A (es) Variantes de factor vii de coagulacion humano.
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
TW200407425A (en) Human coagulation factor VII polypeptides
DE69130679D1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
NZ508505A (en) Treatment of wounds using an Egr-1 transcription factor polypeptide
ATE222101T1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
HUT40695A (en) Dna sequences, recombinant dna molecules and processes for preparing humane lipocortine like polypeptides
BR0213121A (pt) modelo in vitro para atividade priocidal
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
EP0691347A4 (en) GROWTH SUBSTANCE FOR LIVER PARENCHYM CELLS
Wodzicka-Tomaszewska et al. Interactions between stress and boar stimulation in induction of puberty in gilts.
UA10281C2 (uk) Спосіб отримання речовини для лікування захворювань підшлункової залози
KR910016339A (ko) Pp4-델타, 이의 제조방법 및 용도